Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.71 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.69 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.69 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | CD69 | Q07108 | 1/20 | 0.47 |
| ▸ | PTN | P21246 | 1/20 | 0.46 |
| ▸ | MDK | P21741 | 1/20 | 0.46 |
| ▸ | BDNF | P23560 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SELL | P14151 | 1/20 | 0.45 |
| ▸ | IGF2R | P11717 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567492 | 0.96 | MAPK1 (0.79) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL15028496 | 0.89 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4IGF2R | |
| SCHEMBL15081918 | 0.89 | LGALS3 (0.69) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL10106219 | 0.89 | LGALS3 (0.69) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL24943521 | 0.88 | MAPK1 (0.90) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL28256795 | 0.88 | MAPK1 (0.90) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL13786399 | 0.88 | MAPK1 (0.90) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL14010278 | 0.88 | MAPK1 (0.90) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL18947590 | 0.88 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL14380157 | 0.88 | LGALS3 (0.88) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303363-A1 | Preparation and Use of Isolactosamine and Intermediates therefor | GLYCOM A/S (DK) | 2014-10-09 | — | — | US | disclosed |
| WO-2013083136-A1 | PREPARATION AND USE OF ISOLACTOSAMINE AND INTERMEDIATES THEREFOR | GLYCOM A/S (DK) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303363-A1 | Preparation and Use of Isolactosamine and Intermediates therefor | GALE, B4GALT1, GNE | MAPK1 1099/4885LGALS3 53/4885LGALS8 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.